← Leaderboards
Jeffrey H Stern
Regenerative Research Foundation
$6,416,156
Attributed
$7,280,868
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,280,868 · 6
By mechanism
UH3$2,549,156 · 1
R42$1,729,424 · 1
R01$1,687,250 · 1
U01$888,966 · 1
R41$225,501 · 1
UG3$200,571 · 1
Top collaborators
- Kristina Roberts2 shared
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsStructure Of Retinal Pigment EpitheliumSafetyAdultBlindnessAge Related Macular DegenerationTransplantationVisionStem CellsCollaborationsTranscriptomicsSourceEffective TherapyProgenitorCollectionNonexudative Age-Related Macular DegenerationCyclic GmpClinical TrialsAnimal ModelElderlyExperimental StudyCell TypeRepairedPathogenesis
Grant awards (15)
Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum$826,379
R42 · FY2024 · GM · contact PI
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$634,049
UH3 · FY2024 · EY · contact PI
Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum$903,045
R42 · FY2023 · GM · contact PI
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$638,369
UH3 · FY2023 · EY · contact PI
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$638,369
UH3 · FY2022 · EY · contact PI
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$638,369
UH3 · FY2021 · EY · contact PI
Characterization of human RPE subpopulations at the single cell level$412,250
R01 · FY2021 · EY · contact PI
Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum$225,501
R41 · FY2021 · GM · contact PI
Characterization of human RPE subpopulations at the single cell level$425,000
R01 · FY2020 · EY · contact PI
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD$326,250
U01 · FY2020 · EY · contact PI
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$200,571
UG3 · FY2020 · EY · contact PI
Characterization of human RPE subpopulations at the single cell level$425,000
R01 · FY2019 · EY · contact PI
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD$338,500
U01 · FY2019 · EY · contact PI
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD$224,216
U01 · FY2019 · EY · contact PI
Characterization of human RPE subpopulations at the single cell level$425,000
R01 · FY2018 · EY · contact PI